Living with lymphedema after breast cancer can feel overwhelming and isolating. The swelling, discomfort, and limited mobility aren’t just physical—they affect your entire quality of life. But what if a gentle, non-invasive therapy could help ease the symptoms? What if it were backed by science—and approved by the FDA?
Meet the LTU-904 Laser Therapy Unit by RianCorp, a device offering new hope to those with post-mastectomy lymphedema.
The LTU-904 is a low-level laser therapy (LLLT) device specifically designed to treat lymphedema—particularly after breast cancer. Developed by RianCorp Pty Ltd, the LTU-904 is the only laser device cleared by the U.S. Food and Drug Administration (FDA) for this specific use. It is also registered on the Australian Register of Therapeutic Goods (ARTG) and used worldwide, including in Korea and the UK.
Unlike surgery or compression-based therapies, this approach uses targeted light energy to reduce swelling and improve lymphatic drainage—without pain or side effects.
FDA clearance means that the device has undergone rigorous review and met the standards for safety and efficacy. For people navigating the sea of “alternative” lymphedema treatments, this stamp of approval matters.
Researchers evaluated the LTU-904 in the world’s first randomized, double-blind clinical trial for lymphedema therapy. Conducted at Flinders Medical Centre in South Australia and published in the respected journal Cancer (2003), the study produced compelling results:
These aren’t anecdotal results. This is peer-reviewed data—the kind rarely seen in the field of lymphedema care.
This therapy may be especially beneficial for:
Whether you’re newly diagnosed or have lived with chronic lymphedema for years, your healthcare provider may help you explore LTU-904.
The therapy is painless, safe, and fast. The LTU-904 emits invisible infrared light, targeting underlying tissues to stimulate lymphatic function and reduce inflammation.
Most importantly, the researchers specifically designed it to manage ongoing symptoms and extend beyond a one-time intervention.
Ann Angel and Richard Walmsley founded RianCorp in 1998, and the company remains deeply committed to patient outcomes—not hype. Their mission is to design medical laser products that:
Ultimately, they ground their legacy not only in authenticity and care but also in consistently delivering real solutions to those living with lymphatic complications.
Q. Is the LTU-904 safe for home use?
A: Yes, healthcare providers prescribe the LTU-904 for safe use. Moreover, it is non-invasive, and importantly, it does not cause tissue damage; furthermore, it has no known long-term side effects.
Q. How long does it take to see results?
A: Many patients notice improvements in swelling and limb heaviness within a few weeks, and the 2003 clinical trial demonstrated that these improvements continued for at least three months after treatment ended.
Q. Can I use LTU-904 in conjunction with other therapies?
A: Yes. Many patients combine LTU-904 laser therapy with manual lymphatic drainage or compression garments for a more comprehensive approach. Always consult your lymphedema specialist.
Q. Is this covered by insurance?
A: Coverage varies by region and insurer. You may want to discuss with your doctor or insurance provider, especially if you’re based in the U.S., Australia, or the UK.
Q. Where can I buy or learn more about LTU-904?
A: Visit www.riancorp.com or speak with your lymphedema therapist or oncologist about the LTU-904 as part of your treatment plan.
Chronic lymphedema after breast cancer is more than a side effect—it can feel like a lifelong sentence. But you’re not alone. And you’re not without choices.
The LTU-904 offers a scientifically supported, FDA-cleared therapy that may bring relief—without pain, pills, or invasive procedures.
This isn’t just about light. It’s about hope.
Share This Story, Choose Your Platform!